サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1751299

心臓バイオマーカーの市場規模、シェア、動向分析レポート：タイプ別、用途別、最終用途別、地域別、セグメント予測、2025年～2030年

Cardiac Biomarkers Market Size, Share & Trends Analysis Report By Type (Troponin, CK-MB, Myoglobin, BNP and NT-proBNP, Others), By Application, By End Use, By Region, And Segment Forecasts, 2025 - 2030

出版日
ページ情報
英文 100 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.35円
心臓バイオマーカーの市場規模、シェア、動向分析レポート：タイプ別、用途別、最終用途別、地域別、セグメント予測、2025年～2030年
出版日: 2025年05月05日
発行: Grand View Research
ページ情報: 英文 100 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

心臓バイオマーカー市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の心臓バイオマーカー市場は2030年までに511億9,000万米ドルに達し、予測期間中にCAGR 14.1％で拡大すると予測されています。

急性冠症候群（ACS）の有病率の増加は、バイオマーカー技術の進歩とともに、市場成長を促進すると予想されています。心疾患の早期診断と予後に関する意識の高まりは、市場をさらに牽引すると予想されます。

クリーブランド・クリニックの報告書によると、米国では1,800万人以上の成人が冠動脈性心疾患に罹患しています。胸痛は救急外来を受診する最も一般的な理由の一つです。心臓病は米国における主要な死因のひとつであり、41秒に1人が心臓発作を起こしていると推定されています。心臓バイオマーカーはACS診断に重要な役割を果たし、より迅速な治療方針の決定を可能にします。

急性冠症候群のリスク層別化と診断にバイオマーカーの採用が増加しており、需要が増加しています。不健康なライフスタイルが急性冠症候群と心筋梗塞の有病率を高めています。PoC診断の採用増加により、心臓マーカーの使用が容易になり、セグメント革新が促進されています。病院やPoCにおける心臓バイオマーカーの採用におけるパラダイムシフトは、心筋トロポニンIと心筋トロポニンの感度に関する最近のアッセイ開発の動向に起因しています。

心臓バイオマーカー市場レポートハイライト

  • タイプ別では、トロポニンセグメントが、心血管疾患診断におけるその高い使用率により、2024年に35.5%超の最大の収益シェアを占めました。
  • 用途別では、急性冠症候群分野が2025～2030年に最も速いCAGRで成長すると予測されます。
  • 最終用途では、ラボ検査分野が2024年の市場を独占しました。
  • 北米が2024年に世界市場を独占したのは、診断と予後のツールとして心臓バイオマーカーの採用を容易にする医療制度が発達しているためです。
  • 心臓バイオマーカー市場に参入している主な企業は、Abbott、Quidel Corporation、Siemens Healthcare GmbH、F. Hoffmann-La Roche Ltd、Danaher、BIOMERIEUX、Bio-Rad Laboratories Inc、Randox Laboratories Ltd、Creative Diagnostics、Life Diagnosticsなどです。
  • 新規アッセイの利用可能性の増加は、今後数年間の市場成長を促進すると予想される主要な要因の1つです。例えば、2023年10月、Mindrayは2つの高感度心臓バイオマーカーアッセイ、hs-cTnIアッセイとNT-proBNPアッセイを発売しました。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 心臓バイオマーカー市場の変数、動向、範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • 心臓バイオマーカー市場分析ツール
    • 業界分析- ポーターのファイブフォース分析
    • PESTEL分析
  • 心臓バイオマーカー市場：パイプライン分析

第4章 心臓バイオマーカー市場：タイプ別推定・動向分析

  • セグメントダッシュボード
  • 心臓バイオマーカー市場：変動分析
  • 世界の心臓バイオマーカー市場規模と動向分析（2018～2030年）
  • トロポニン
  • CK-MB
  • ミオグロビン
  • 不可逆的電気穿孔アブレーション
  • BNPとNT-PROBNP
  • その他

第5章 心臓バイオマーカー市場：用途別推定・動向分析

  • セグメントダッシュボード
  • 心臓バイオマーカー市場：変動分析
  • 世界の心臓バイオマーカー市場規模と動向分析（2018～2030年）
  • 急性冠症候群
  • 心筋梗塞
  • うっ血性心不全
  • その他

第6章 心臓バイオマーカー市場：最終用途別推定・動向分析

  • セグメントダッシュボード
  • 心臓バイオマーカー市場：変動分析
  • 世界の心臓バイオマーカー市場規模と動向分析（2018～2030年）
  • 臨床検査
  • ポイントオブケア検査

第7章 心臓バイオマーカー市場：地域推定・動向分析

  • 地域市場ダッシュボード
  • 地域別市場シェア分析、2024年および2030年
  • 地域別市場：主なポイント
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • ノルウェー
    • スウェーデン
    • デンマーク
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • オーストラリア
    • 韓国
    • タイ
  • ラテンアメリカ
    • ブラジル
    • アルゼンチン
  • 中東・アフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第8章 競合情勢

  • 主要市場参入企業による最近の動向と影響分析
  • 企業/競合の分類
  • ベンダー情勢
  • 企業プロファイル
    • Abbott
    • Quidel Corporatio
    • Siemens Healthcare Gmbh
    • F. Hoffmann-La Roche Ltd.
    • Danaher
    • BIOMERIEUX
    • Bio-Rad Laboratories, Inc.
    • Randox Laboratories Ltd.
    • Creative Diagnostics
    • Life Diagnostics
図表

List of Tables

  • Table 1 List of abbreviations
  • Table 2 North America cardiac biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 3 North America cardiac biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 4 North America cardiac biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 5 North America cardiac biomarkers market, by region, 2018 - 2030 (USD Million)
  • Table 6 U.S cardiac biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 7 U.S cardiac biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 8 U.S cardiac biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 9 Canada cardiac biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 10 Canada cardiac biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 11 Canada cardiac biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 12 Europe cardiac biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 13 Europe cardiac biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 14 Europe cardiac biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 15 Europe cardiac biomarkers market, by region, 2018 - 2030 (USD Million)
  • Table 16 Germany cardiac biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 17 Germany cardiac biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 18 Germany cardiac biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 19 UK cardiac biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 20 UK cardiac biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 21 UK cardiac biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 22 France cardiac biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 23 France cardiac biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 24 France cardiac biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 25 Italy cardiac biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 26 Italy cardiac biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 27 Italy cardiac biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 28 Spain cardiac biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 29 Spain cardiac biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 30 Spain cardiac biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 31 Denmark cardiac biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 32 Denmark cardiac biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 33 Denmark cardiac biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 34 Sweden cardiac biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 35 Sweden cardiac biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 36 Sweden cardiac biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 37 Norway cardiac biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 38 Norway cardiac biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 39 Norway cardiac biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 40 Asia Pacific cardiac biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 41 Asia Pacific cardiac biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 42 Asia Pacific cardiac biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific cardiac biomarkers market, by region, 2018 - 2030 (USD Million)
  • Table 44 Japan cardiac biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 45 Japan cardiac biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 46 Japan cardiac biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 47 China cardiac biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 48 China cardiac biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 49 China cardiac biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 50 India cardiac biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 51 India cardiac biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 52 India cardiac biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 53 Australia cardiac biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 54 Australia cardiac biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 55 Australia cardiac biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 56 Thailand cardiac biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 57 Thailand cardiac biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 58 Thailand cardiac biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 59 South Korea cardiac biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 60 South Korea cardiac biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 61 South Korea cardiac biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 62 Latin America cardiac biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 63 Latin America cardiac biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 64 Latin America cardiac biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 65 Latin America cardiac biomarkers market, by region, 2018 - 2030 (USD Million)
  • Table 66 Brazil cardiac biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 67 Brazil cardiac biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 68 Brazil cardiac biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 69 Mexico cardiac biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 70 Mexico cardiac biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 71 Mexico cardiac biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 72 Argentina cardiac biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 73 Argentina cardiac biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 74 Argentina cardiac biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 75 Middle East and Africa cardiac biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 76 Middle East and Africa cardiac biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 77 Middle East and Africa cardiac biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 78 Middle East and Africa cardiac biomarkers market, by region, 2018 - 2030 (USD Million)
  • Table 79 South Africa cardiac biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 80 South Africa cardiac biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 81 South Africa cardiac biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 82 Saudi Arabia cardiac biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 83 Saudi Arabia cardiac biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 84 Saudi Arabia cardiac biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 85 UAE cardiac biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 86 UAE cardiac biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 87 UAE cardiac biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 88 Kuwait cardiac biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 89 Kuwait cardiac biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 90 Kuwait cardiac biomarkers market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 QFD modeling for market share assessment
  • Fig. 6 Market formulation & validation
  • Fig. 7 Cardiac biomarkers: Market outlook
  • Fig. 8 Cardiac biomarkers: Competitive insights
  • Fig. 9 Parent market outlook
  • Fig. 10 Related/ancillary market outlook
  • Fig. 11 Penetration and growth prospect mapping
  • Fig. 12 Cardiac biomarkers market driver impact
  • Fig. 13 Cardiac biomarkers market restraint impact
  • Fig. 14 Cardiac biomarkers market strategic initiatives analysis
  • Fig. 15 Cardiac biomarkers market: Type movement analysis
  • Fig. 16 Cardiac biomarkers market: Type outlook and key takeaways
  • Fig. 17 Troponin market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 18 CK-MB market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 19 Myoglobin market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 BNP and NT-proBNP market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Cardiac biomarkers market: Application movement analysis
  • Fig. 23 Cardiac biomarkers market: Application outlook and key takeaways
  • Fig. 24 Acute coronary syndrome market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Myocardial infarction market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Congestive heart failure market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Other applications market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Cardiac biomarkers market: End use movement analysis
  • Fig. 29 Cardiac biomarkers market: End use outlook and key takeaways
  • Fig. 30 Laboratory testing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Point of care testing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Pain management market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Cancer therapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Vaccine delivery market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Other end use market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Global cardiac biomarkers market: Regional movement analysis
  • Fig. 37 Global cardiac biomarkers market: Regional outlook and key takeaways
  • Fig. 38 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 U.S market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
目次
Product Code: GVR-1-68038-083-5

Cardiac Biomarkers Market Growth & Trends:

The global cardiac biomarkers market is anticipated to reach USD 51.19 billion by 2030 and is anticipated to expand at a CAGR of 14.1% during the forecast period, according to a new report by Grand View Research, Inc. The increasing prevalence of acute coronary syndrome (ACS), along with advancements in biomarker technologies, is expected to propel market growth. The rising awareness regarding early diagnosis and prognosis of cardiac diseases is expected to further drive the market.

According to the report by Cleveland Clinic, more than 18 million adults in the U.S. were affected by coronary heart disease. Chest pain is one of the most common reasons for emergency department visits. Heart disease is one of the major causes of death in the U.S., and it is estimated that a person has a heart attack every 41 seconds. Cardiac biomarkers play a significant role in ACS diagnosis and facilitate faster treatment decision-making, thereby making them crucial.

The rising adoption of biomarkers in risk stratification and diagnosis of acute coronary syndrome is increasing the demand. An unhealthy lifestyle is driving the prevalence of acute coronary syndrome and myocardial infarction. The increasing adoption of PoC diagnostics is driving segment innovation, making the use of cardiac markers easier. The paradigm shift in the adoption of cardiac biomarkers in hospitals and PoC settings can be attributed to the recent developments in assays pertaining to the sensitivity of cardiac troponin I and cardiac troponin.

Cardiac Biomarkers Market Report Highlights:

  • In terms of type, the troponin segment held the largest revenue share of over 35.5% in 2024 owing to its high usage in cardiovascular disease diagnosis
  • Based on application, the acute coronary syndrome segment is expected to grow at the fastest CAGR during 2025 - 2030
  • In terms of end use, laboratory testing segment dominated the market in 2024
  • North America dominated the global market in 2024 owing to the presence of a developed healthcare system that facilitates easier adoption of cardiac biomarkers as a tool for diagnosis and prognosis
  • Key players operating in the cardiac biomarkers market include Abbott, Quidel Corporation, Siemens Healthcare GmbH, F. Hoffmann-La Roche Ltd, Danaher, BIOMERIEUX, Bio-Rad Laboratories Inc, Randox Laboratories Ltd, Creative Diagnostics, Life Diagnostics
  • The rise in the availability of novel assays is one of the major drivers anticipated to boost market growth in the upcoming years. For instance, in October 2023, Mindray launched two highly sensitive cardiac biomarkers assays, hs-cTnI Assay, and NT-proBNP Assay, to diversify its portfolio in cardio biomarkers to provide enhanced cardiovascular disease care.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Application
    • 1.2.3. End Use
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Type
    • 2.2.2. Application
    • 2.2.3. End Use
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Cardiac Biomarkers Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market outlook
    • 3.1.2. Related/ancillary Market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. Cardiac Biomarkers Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
  • 3.4. Cardiac Biomarkers Market : Pipeline Analysis

Chapter 4. Cardiac Biomarkers Market : Type Estimates & Trend Analysis

  • 4.1. Type Segment Dashboard
  • 4.2. Cardiac Biomarkers Market: Type Movement Analysis
  • 4.3. Global Cardiac Biomarkers Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
  • 4.4. Troponin
    • 4.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5. CK-MB
    • 4.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.6. Myoglobin
    • 4.6.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.7. Irreversible Electroporation Ablation
    • 4.7.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.8. BNP AND NT-PROBNP
    • 4.8.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.9. Others
    • 4.9.1. Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Cardiac Biomarkers Market : Application Estimates & Trend Analysis

  • 5.1. Application Segment Dashboard
  • 5.2. Cardiac Biomarkers Market: Application Movement Analysis
  • 5.3. Global Cardiac Biomarkers Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
  • 5.4. Acute Coronary Syndrome
    • 5.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.5. Myocardial Infarction
    • 5.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.6. Congestive Heart Failure
    • 5.6.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.7. Others
    • 5.7.1. Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Cardiac Biomarkers Market: End Use Estimates & Trend Analysis

  • 6.1. End Use Segment Dashboard
  • 6.2. Cardiac Biomarkers Market: End Use Movement Analysis
  • 6.3. Global Cardiac Biomarkers Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
  • 6.4. Laboratory Testing
    • 6.4.1. Market estimates and forecasts, 2018 to 2030 (USD million)
  • 6.5. Point of Care Testing
    • 6.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. Cardiac Biomarkers Market : Regional Estimates & Trend Analysis

  • 7.1. Regional Market Dashboard
  • 7.2. Regional Market Share Analysis, 2024 & 2030
  • 7.3. Continuous bioprocessing Market by Region: Key Takeaways
  • 7.4. North America
    • 7.4.1. U.S.
      • 7.4.1.1. Key country dynamics
      • 7.4.1.2. Regulatory framework/ reimbursement structure
      • 7.4.1.3. Competitive scenario
      • 7.4.1.4. U.S. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.2. Canada
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Regulatory framework/ reimbursement structure
      • 7.4.2.3. Competitive scenario
      • 7.4.2.4. Canada Market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.3. Mexico
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Regulatory framework/ reimbursement structure
      • 7.4.3.3. Competitive scenario
      • 7.4.3.4. Mexico Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.5. Europe
    • 7.5.1. UK
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. UK Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.5.2. Germany
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. Germany Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.5.3. France
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. France Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.5.4. Italy
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework/ reimbursement structure
      • 7.5.4.3. Competitive scenario
      • 7.5.4.4. Italy Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.5.5. Spain
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Regulatory framework/ reimbursement structure
      • 7.5.5.3. Competitive scenario
      • 7.5.5.4. Spain Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.5.6. Norway
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Regulatory framework/ reimbursement structure
      • 7.5.6.3. Competitive scenario
      • 7.5.6.4. Norway Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.5.7. Sweden
      • 7.5.7.1. Key country dynamics
      • 7.5.7.2. Regulatory framework/ reimbursement structure
      • 7.5.7.3. Competitive scenario
      • 7.5.7.4. Sweden Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.5.8. Denmark
      • 7.5.8.1. Key country dynamics
      • 7.5.8.2. Regulatory framework/ reimbursement structure
      • 7.5.8.3. Competitive scenario
      • 7.5.8.4. Denmark Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Japan
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. Japan Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.6.2. China
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. China Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.6.3. India
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Regulatory framework/ reimbursement structure
      • 7.6.3.3. Competitive scenario
      • 7.6.3.4. India Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.6.4. Australia
      • 7.6.4.1. Key country dynamics
      • 7.6.4.2. Regulatory framework/ reimbursement structure
      • 7.6.4.3. Competitive scenario
      • 7.6.4.4. Australia Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.6.5. South Korea
      • 7.6.5.1. Key country dynamics
      • 7.6.5.2. Regulatory framework/ reimbursement structure
      • 7.6.5.3. Competitive scenario
      • 7.6.5.4. South Korea Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.6.6. Thailand
      • 7.6.6.1. Key country dynamics
      • 7.6.6.2. Regulatory framework/ reimbursement structure
      • 7.6.6.3. Competitive scenario
      • 7.6.6.4. Thailand Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Brazil
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. Brazil Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.7.2. Argentina
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Argentina Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.8. MEA
    • 7.8.1. South Africa
      • 7.8.1.1. Key country dynamics
      • 7.8.1.2. Regulatory framework/ reimbursement structure
      • 7.8.1.3. Competitive scenario
      • 7.8.1.4. South Africa Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.8.2. Saudi Arabia
      • 7.8.2.1. Key country dynamics
      • 7.8.2.2. Regulatory framework/ reimbursement structure
      • 7.8.2.3. Competitive scenario
      • 7.8.2.4. Saudi Arabia Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.8.3. UAE
      • 7.8.3.1. Key country dynamics
      • 7.8.3.2. Regulatory framework/ reimbursement structure
      • 7.8.3.3. Competitive scenario
      • 7.8.3.4. UAE Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.8.4. Kuwait
      • 7.8.4.1. Key country dynamics
      • 7.8.4.2. Regulatory framework/ reimbursement structure
      • 7.8.4.3. Competitive scenario
      • 7.8.4.4. Kuwait Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. Key company heat map analysis, 2024
  • 8.4. Company Profiles
    • 8.4.1. Abbott
      • 8.4.1.1. Company overview
      • 8.4.1.2. Financial performance
      • 8.4.1.3. Product benchmarking
      • 8.4.1.4. Strategic initiatives
    • 8.4.2. Quidel Corporatio
      • 8.4.2.1. Company overview
      • 8.4.2.2. Financial performance
      • 8.4.2.3. Product benchmarking
      • 8.4.2.4. Strategic initiatives
    • 8.4.3. Siemens Healthcare Gmbh
      • 8.4.3.1. Company overview
      • 8.4.3.2. Financial performance
      • 8.4.3.3. Product benchmarking
      • 8.4.3.4. Strategic initiatives
    • 8.4.4. F. Hoffmann-La Roche Ltd.
      • 8.4.4.1. Company overview
      • 8.4.4.2. Financial performance
      • 8.4.4.3. Product benchmarking
      • 8.4.4.4. Strategic initiatives
    • 8.4.5. Danaher
      • 8.4.5.1. Company overview
      • 8.4.5.2. Financial performance
      • 8.4.5.3. Product benchmarking
      • 8.4.5.4. Strategic initiatives
    • 8.4.6. BIOMERIEUX
      • 8.4.6.1. Company overview
      • 8.4.6.2. Financial performance
      • 8.4.6.3. Product benchmarking
      • 8.4.6.4. Strategic initiatives
    • 8.4.7. Bio-Rad Laboratories, Inc.
      • 8.4.7.1. Company overview
      • 8.4.7.2. Financial performance
      • 8.4.7.3. Product benchmarking
      • 8.4.7.4. Strategic initiatives
    • 8.4.8. Randox Laboratories Ltd.
      • 8.4.8.1. Company overview
      • 8.4.8.2. Financial performance
      • 8.4.8.3. Product benchmarking
      • 8.4.8.4. Strategic initiatives
    • 8.4.9. Creative Diagnostics
      • 8.4.9.1. Company overview
      • 8.4.9.2. Financial performance
      • 8.4.9.3. Product benchmarking
      • 8.4.9.4. Strategic initiatives
    • 8.4.10. Life Diagnostics
      • 8.4.10.1. Company overview
      • 8.4.10.2. Financial performance
      • 8.4.10.3. Product benchmarking
      • 8.4.10.4. Strategic initiatives